Skip to content

Medication errors common among hospitalised HIV patients

Genetic marker predicts liver harm from nevirapine or efavirenz

Severe immune suppression linked to poorer CD4 cell response with virologically successful HAART

Adherence to non-nucleoside-based regimens may be less demanding

Panacos finds oral fusion inhibitors, provides development update on bevirimat

Draft BHIVA treatment guidelines: respond by Monday September 4th

Many HIV-positive patients in London risking their health by use of alternative therapies

Final results confirm twice-daily boosted fosamprenavir is comparable to twice-daily Kaletra in treatment-naive

Needle-free mode of T-20 dosing looks highly satisfactory for patients